Journal of Preventive Medicine and Public Health

The Korean Society for Preventive Medicine (대한예방의학회)
권호 표지

Estimating the Cost Savings Due to the Effect of Kremezin in Delaying the Initiation of Dialysis Treatments among Patients with Chronic Renal Failure

크레메진의 투석도입 지연효과에 따른 진행성 신부전증환자의 비용감소분 추계

  • Cho, Woo-Hyun (Department of Preventive Medicine, College of Medicine, Yonsei University) ;
  • Lee, Sun-Mi (Department of Public Health, Graduate School of Yonsei University) ;
  • Kim, Hyung-Jong (Department of Internal Medicine, College of Medicine, Pochon Cha University) ;
  • Lee, Ho-Yong (Department of Internal Medicine, College of Medicine, Yonsei University) ;
  • Woo, Tae-Wook (Pharmaceutical Business Unit, Marketing Department, CJ Corporation) ;
  • Kang, Hye-Young (Graduate School of Public Health, Yonsei University)
  • 조우현 (연세대학교 의과대학 예방의학교실) ;
  • 이선미 (연세대학교 대학원 보건학과) ;
  • 김형종 (포천중문 의과대학 내과학교실) ;
  • 이호영 (연세대학교 의과대학 내과학교실) ;
  • 우태욱 (씨제이 주식회사) ;
  • 강혜영 (연세대학교 보건대학원)
  • Published : 2006.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : We wanted to evaluate the economic value of a pharmaceutical product, Kremezin, for treating patients with chronic renal failure (CRF) by estimating the amount of cost savings due to its effect for delaying the initiation of dialysis treatments. Methods : We defined a conventional treatment for CRF accompanied by Kremezin therapy as 'the treatment group' and only conventional treatment as 'the alternative group.' The types of costs included were direct medical and nonmedical costs and costs of productivity loss. The information on the effect of Kremezin was obtained from the results of earlier clinical studies. Cost information was derived from the administrative data for 20 hemodialysis and 20 peritoneal dialysis patients from one tertiary care hospital, and also from the administrative data of 10 hemodialysis patients from one free-standing dialysis center. Per-capita cost savings resulting from Kremezin therapy were separately estimated for the cases with delay for the onset of hemodialysis and the cases with immediate performance of peritoneal dialysis. By computing the weighted average for the cases of hemodialysis and peritoneal dialysis, the expected per-capita cost savings of a patient with CRF was obtained. Using a discount rate of 5%, future cost savings were converted to the present value. Results : The present value of cumulative cost savings per patient with CRF from the societal perspective would be $18,555,000{\sim}29,410,000$ Won or $72,104,000{\sim}112,523,000$ Won if Kremezin delays the initiation of dialysis by 1 or 4 years. Conclusions : The estimated amount of cost savings resulting from treating CRF patients with Kremezin confirms that its effect for delaying the onset of dialysis treatments has a considerable economic value.

Keywords

References

  1. 연세대학교 신장질환연구소 편저. 신장학의학문화사; 1999
  2. Goldman L, Ausiello D. Ch 117. Chronic Renal Failure. In: Cecil Textbook of Medicine. 22nd ed. Philadelphia: Saunders; 2004. pp708-716
  3. Kim JC, Jo ST, Yoon JY, Kim GH, Jeon RW, Kim HJ, Chae DW, Noh JW, Son BK, Koo JR. Depression in chronic hemodialysis patients: risk factors and effects on nutritional parameters. Korean J Intern Med 2002; 62(1): 77-82 (Korean)
  4. Min HJ, Ko KS, Kim MS, Moon SS, Park WD, Park CW, Suh SY, Yu BH, Lee YK, Chung TS, Shin YT. The influencing factors of quality of life in hemodialysis patients. Korean J Nephrol 1999; 18(5): 714-732 (Korean)
  5. Neto JF, Ferraz ME, Cendoroglo M, Draibe S, Yu L, Sesso R. Quality of life at the initiation of maintenance dialysis treatment: a comparison between the SF- 36 and the KDQ question. Qual Life Res 2000; 9: 101-107 https://doi.org/10.1023/A:1008918609281
  6. Sesso R, Rodrigues-Neto JF, Ferraz MB. Impact of socioeconomic status on the quality of life of ESRD patients. Am J Kidney Dis 2003; 41(1): 186-195 https://doi.org/10.1053/ajkd.2003.50003
  7. Mittal SK, Ahern L, Flaster E, Maesaka JK, Fishbane S. Self-assessed quality of life in peritoneal dialysis patients. Am J Nephrol 2001; 21(3): 215-220 https://doi.org/10.1159/000046250
  8. Kobayashi N, Maeda A, Horikoshi S, Shirato I, Tomino Y, Ise M. Effects of oral adsorbent AST-120 (Kremezin) on renal function and glomerular injury in early-stage renal failure of subtotal nephrectomized rats. Nephron 2002; 91(3): 480-485 https://doi.org/10.1159/000064291
  9. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxylsulfate levels in undialyzed uremic patients. Kidney Int 1997;62:23-28
  10. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulate the progression of glomerular sclerosis. J Lab Clin Med 1994; 124(1): 96-104
  11. Yoshida Y, Sakai T, Ise M. Effects of oral adsorbent in the rat model of chronic renal failure. Nephron 1992; 62(3): 305-314 https://doi.org/10.1159/000187065
  12. Motojima M, Nishijima F, Ikoma M, Kawamura T, Yoshioka T, Fogo AB, Sakai T, Ichikawa I. Role for 'uremic toxin' in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40(3): 461-469 https://doi.org/10.1038/ki.1991.233
  13. Yoshinobu T, Toshio O, Norihiro S. Effect of Kremezinon diabetic renal failure. J Pract Diabet 2003; 20(6): 721-725 (Japanese)
  14. Naoki M, Hidetaka N, Katsutoshi K. Effect of oral adsorbent on diabetic renal failure patients with relation to level of serum bete-2-microglobulin at the time of first prescription of the drug. Kidney Dial 2002; 53(3): 397-402 (Japanese)
  15. Chizuru I, Michiko K, Sanae I. Estimating the effect of oraladsorbent AST-120 on delay of the initiation of dialysis in patients with chronic renal failure. Prog Med 2000; 20: 2047-2050 (Japanese)
  16. Shoze K, Keizo K, Yoshiji Y. The effect of AST-120 on delaying initiation of dialysis therapy in end-stage renal disease. Dialysis 1992; 32(5): 119-130 (Japanese)
  17. Mitch WE, Walser M, Buffington GA, Lemann J Jr. A simple method of estimating progression of chronic renal failure. Lancet 1976; 2(7999): 1326-1328
  18. Owada A, Nakao M, Koike J, Ujiie K, Tomita K, Shiigai T. Effect of oral adsorbent AST-120 on the progression of chronic renal failure: A randomized controlled study. Kidney Int 1997; 63: S188-S190
  19. Yorioka N, Ito T, Masaki T, Ogata S, Asakimori Y, Tanji C, Kyuden Y, Komiya Y, Kumagai J, Janjguchi Y, Kohno N. Dosedependent effect of an oral adsorbent, AST-120, in patients with early chronic renal failure. J Int Med Res 2002; 30: 467-475 https://doi.org/10.1177/147323000203000501
  20. Yoshinobu E, Toshio O, Norihiro S, Shyuuka U. Effect of Kremezin on diabetic renal failure. J Pract Diabet 2003; 20(60): 721-725
  21. Owada a, Shiigai T. Effects of oral adsorbent AST-120 concurrent with a low-protein diet on the progression of chronic renal failure. Am J Nephrol 1996; 16; 124-127 https://doi.org/10.1159/000168983
  22. Institute of Health Services Research, Yonsei University. Evaluation of the Economic Value of the Sirolimus Eluting Stent (CYPHER^{TM}$) in Acute Coronary Heart Disease: Results of Korea. 2002
  23. Korean Society of Nephrology. http://www.ksn.or.kr/yo/yo_m_2.htm. October, 2003
  24. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programs. Oxford Medical Publications 2nd Ed; 1997
  25. Korean National Statistical Office. Gender -and Age-Specific Labor Force Participation, 2002
  26. Gutman RA, Stead WW, Robinson RR. Physical activity and employment status of patients on maintenance dialysis. N Engl J Med 1981; 304(6): 309-313 https://doi.org/10.1056/NEJM198102053040601